Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yaron Perry

Surgery Buffalo, NY Medical Doctor

NPI 1508013608 CMS profile 605127

462 Grider St, Buffalo, NY 14215

Open in the dashboard

General payments

$24,321

138 records reported · program years 2019–2025

Research payments

$13,350

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yaron Perry of Buffalo, NY is reported in the CMS Open Payments database as having received $24,321 across 138 general payments and $13,350 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,597 22
2024 General $12,524 36
2023 General $1,183 18
2022 General $657 13
2021 General $3,375 22
2021 Research $13,350 1
2020 General $186 6
2019 General $3,799 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yaron Perry
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Yaron Perry were reported at $2,597. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Yaron Perry Surgery median Middle half National median
2019 $3,799 $253 $82–$1,521 $163
2020 $186 $131 $40–$706 $114
2021 $3,375 $168 $50–$904 $132
2022 $657 $224 $76–$1,218 $149
2023 $1,183 $253 $82–$1,255 $160
2024 $12,524 $279 $90–$1,381 $164
2025 $2,597 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $9,972 37 payments
  2. AstraZeneca Pharmaceuticals LP $7,111 6 payments
  3. Becton, Dickinson and Company $2,112 9 payments
  4. Medtronic, Inc. $1,922 18 payments
  5. AOP Health US, LLC $542 1 payment
  6. Galvanize Therapeutics, Inc $470 4 payments
  7. Atricure, Inc. $383 16 payments
  8. Ethicon US, LLC $238 4 payments
  9. Lucid Diagnostics Inc. $232 3 payments
  10. Bard Access Systems, Inc. $203 2 payments
  11. Other $1,136 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,945 38 payments
  2. Food and Beverage $5,875 94 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,390 4 payments
  4. Education $2,500 1 payment
  5. Consulting Fee $1,611 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $9,972 37 payments
  2. IMFINZI $5,000 3 payments
  3. TAGRISSO $2,111 3 payments
  4. Progel Applicator Spray Tips $2,095 9 payments
  5. Rapiblyk Cardiovascular $542 1 payment
  6. Rapiblyk Cardiovascular $542 1 payment
  7. ALIYA SYSTEM $470 4 payments
  8. ECHELON FLEX Stapler $187 2 payments
  9. PROGEL $181 1 payment
  10. SYNERGY ABLATION SYSTEM $172 7 payments
  11. Other $2,073 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $13,350 1 payment

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$28,188

Medicare's payments for the services billed

Medicare patients

82

Average age 73

Services billed

180

44 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Cancer 57%
COPD 54%
Ischemic heart disease 50%
Arthritis 50%
Chronic kidney disease 40%
Heart failure 33%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $5,000
$5,000 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $500
$500 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record